Drugs facing NCE-1 in 2023

1. Accrufer patent expiration

ACCRUFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(6 years from now)

US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 26 July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE

More Information on Dosage

ACCRUFER family patents

Family Patents

2. Aklief patent expiration

AKLIEF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Jul, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 20 days from now)

US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 20 days from now)

US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid
May, 2033

(8 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 04, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 05 October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris

Dosage: CREAM

More Information on Dosage

AKLIEF family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Aubagio patent expiration

AUBAGIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5459163 SANOFI AVENTIS US Medicament to combat autoimmune diseases
Oct, 2012

(12 years ago)

US5679709 SANOFI AVENTIS US Medicaments to combat autoimmune diseases
Oct, 2014

(10 years ago)

US6794410 SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Sep, 2026

(1 year, 9 months from now)

US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Mar, 2027

(2 years from now)

US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Sep, 2030

(5 years from now)

US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Mar, 2031

(6 years from now)

US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Feb, 2034

(9 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Aug, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 12, 2017
M(M-61) Apr 30, 2024
Pediatric Exclusivity(PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...

Dosage: TABLET

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

4. Austedo patent expiration

AUSTEDO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)

US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(6 years from now)

US11666566 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US11666566

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US11446291 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11564917 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US12016858 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11357772 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US12016858

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(11 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(11 years from now)

US11564917

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(11 years from now)

US11648244

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(11 years from now)

US11446291

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(11 years from now)

US11357772

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(11 years from now)

US11813232 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(13 years from now)

US11813232

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE) Apr 03, 2024
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Pediatric Exclusivity(PED) Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

5. Balversa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(6 years from now)

US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(10 years from now)

US12037644 JANSSEN BIOTECH Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor
Oct, 2035

(10 years from now)

US11684620 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(11 years from now)

US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(11 years from now)

US10478494 JANSSEN BIOTECH FGFR/PD-1 combination therapy for the treatment of cancer
Aug, 2036

(11 years from now)

US11077106 JANSSEN BIOTECH Cancer treatment
Feb, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2024
New Indication(I-930) Jan 19, 2027

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 13 April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...

Dosage: TABLET

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

6. Brukinsa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11851437 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

US11970500 BEIGENE Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11884674 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11591340 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11701357 BEIGENE Treatment of B cell cancers using a combination comprising Btk inhibitors
Jun, 2039

(14 years from now)

US11786531 BEIGENE Methods of treating B-cell proliferative disorder
Jan, 2043

(18 years from now)

US11911386 BEIGENE Methods of treating B-cell proliferative disorder
Jan, 2043

(18 years from now)

US11896596 BEIGENE Methods of treating B-cell proliferative disorder
Jan, 2043

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-871) Aug 31, 2024
New Indication(I-874) Sep 14, 2024
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
New Indication(I-817) Jan 19, 2026
Orphan Drug Exclusivity(ODE-276) Nov 14, 2026
New Indication(I-936) Mar 07, 2027
Orphan Drug Exclusivity(ODE-371) Aug 31, 2028
Orphan Drug Exclusivity(ODE-370) Sep 14, 2028
Orphan Drug Exclusivity(ODE-274) Jan 19, 2030
Orphan Drug Exclusivity(ODE-467) Mar 07, 2031

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 15 November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with relaps...

Dosage: CAPSULE

More Information on Dosage

BRUKINSA family patents

Family Patents

7. Caplyta patent expiration

CAPLYTA's oppositions filed in EPO
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7183282 INTRA-CELLULAR Substituted heterocycle fused γ-carbolines
Jun, 2020

(4 years ago)

USRE39680 INTRA-CELLULAR Substituted heterocycle fused gamma-carbolines
Jun, 2020

(4 years ago)

USRE48825 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(4 years from now)

US9586960 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(4 years from now)

US8648077 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
Mar, 2028

(3 years from now)

US9199995 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Mar, 2029

(4 years from now)

US9168258 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(5 years from now)

USRE48839 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Aug, 2033

(8 years from now)

US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia
Dec, 2034

(10 years from now)

US11026951 INTRA-CELLULAR Methods of treating bipolar disorder
Dec, 2034

(10 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression
Dec, 2034

(10 years from now)

US12128043 INTRA-CELLULAR Pharmaceutical capsules comprising lumateperone mono-tosylate
Aug, 2039

(14 years from now)

US11806348 INTRA-CELLULAR Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(14 years from now)

US11052084 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(14 years from now)

US10695345 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(14 years from now)

US12070459 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(14 years from now)

US11690842 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(14 years from now)

US11980617 INTRA-CELLULAR Methods of treating acute depression and/or acute anxiety
Oct, 2039

(14 years from now)

US12090155 INTRA-CELLULAR Methods
Jul, 2040

(15 years from now)

US11753419 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
Dec, 2040

(16 years from now)

US12122792 INTRA-CELLULAR Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
Dec, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-882) Dec 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 20, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia; Treatment of schizophrenia with improvement in residual symptoms of...

Dosage: CAPSULE

More Information on Dosage

CAPLYTA family patents

Family Patents

8. Dalvance patent expiration

DALVANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7119061 ABBVIE Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(1 year, 17 days ago)

US7115564 ABBVIE Stable pharmaceutical compositions of dalbavancin and methods of administration
Nov, 2023

(1 year, 17 days ago)

US8143212 ABBVIE Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(1 year, 17 days ago)

US6900175 ABBVIE Methods of administering dalbavancin for treatment of bacterial infections
May, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-154) Jan 20, 2019
New Chemical Entity Exclusivity(NCE) May 23, 2019
Generating Antibiotic Incentives Now(GAIN) May 23, 2024
New Patient Population(NPP) Jul 22, 2024

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: 24 May, 2023

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.; Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose re...

Dosage: POWDER

More Information on Dosage

DALVANCE family patents

Family Patents

9. Exem Foam Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities
Oct, 2030

(5 years from now)

US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(10 years from now)

US9849199 GISKIT Composition and method for medical imaging of body cavities
Feb, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 07, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 08 November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM

More Information on Dosage

EXEM FOAM KIT family patents

Family Patents

10. Givlaari patent expiration

GIVLAARI's oppositions filed in EPO
GIVLAARI IPR and PTAB Proceedings
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of a target gene
Jan, 2022

(2 years ago)

US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(10 months ago)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(8 months ago)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(8 months ago)

US11530408 ALNYLAM PHARMS INC Therapeutic compositions
May, 2024

(6 months ago)

US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(8 months from now)

US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(3 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(8 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Nov, 2033

(9 years from now)

US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(9 years from now)

US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION

More Information on Dosage

GIVLAARI family patents

Family Patents

11. Harvoni patent expiration

HARVONI's oppositions filed in EPO
HARVONI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(4 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(4 years from now)

US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(5 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(5 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(5 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(6 years from now)

US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(3 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(3 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(3 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(3 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(4 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(4 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(4 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(4 years from now)

US8273341 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(5 years from now)

US9511056 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(5 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(5 years from now)

US8841278

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(5 years from now)

US8088368

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(5 years from now)

US8273341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(5 years from now)

US9511056

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(5 years from now)

US8822430

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(5 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(6 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(6 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(7 years from now)

US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(7 years from now)

US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV
Mar, 2033

(8 years from now)

US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-153) Nov 12, 2018
New Indication(I-718) Nov 12, 2018
New Indication(I-719) Nov 12, 2018
New Indication(I-720) Nov 12, 2018
New Dosing Schedule(D-158) Feb 12, 2019
New Dosing Schedule(D-159) Feb 12, 2019
New Dosing Schedule(D-160) Feb 12, 2019
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Patient Population(NPP) Apr 07, 2020
New Dosing Schedule(D-177) Nov 15, 2022
Orphan Drug Exclusivity(ODE) Apr 07, 2024
ODE*(ODE*) Aug 28, 2026
Orphan Drug Exclusivity(ODE-136) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE-262) Aug 28, 2026
Orphan Drug Exclusivity(ODE-263) Aug 28, 2026
Orphan Drug Exclusivity(ODE-264) Aug 28, 2026

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c

Dosage: TABLET

More Information on Dosage

HARVONI family patents

Family Patents

12. Ibsrela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(5 years from now)

US12016856 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(5 years from now)

US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
Dec, 2029

(5 years from now)

US9006281 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
May, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 13 September, 2023

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET

More Information on Dosage

IBSRELA family patents

Family Patents

13. Inrebic patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7825246 BRISTOL-MYERS Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(2 years from now)

US7528143 BRISTOL-MYERS Bi-aryl meta-pyrimidine inhibitors of kinases
Nov, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199 BRISTOL-MYERS Use of bi-aryl meta-pyrimidine inhibitors of kinases
Jun, 2028

(3 years from now)

US10391094 BRISTOL-MYERS Compositions and methods for treating myelofibrosis
Jun, 2032

(7 years from now)

US11400092 BRISTOL-MYERS Methods of treating myeloproliferative disorders
Sep, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2024
Orphan Drug Exclusivity(ODE-259) Aug 16, 2026

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...

Dosage: CAPSULE

More Information on Dosage

INREBIC family patents

Family Patents

14. Janumet patent expiration

JANUMET's oppositions filed in EPO
JANUMET IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(1 year, 11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 MSD SUB MERCK Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7459428 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6699871 MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 years ago)

US7125873 MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 years ago)

US7125873

(Pediatric)

MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 10 months ago)

US6699871

(Pediatric)

MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 10 months ago)

US7326708

(Pediatric)

MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(2 years from now)

US8414921 MSD SUB MERCK Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jul, 2028

(3 years from now)

US8414921

(Pediatric)

MSD SUB MERCK Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jan, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2011
M(M-244) Aug 12, 2022
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Jun 04, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...

Dosage: TABLET

How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage

JANUMET family patents

Family Patents

15. Januvia patent expiration

JANUVIA's oppositions filed in EPO
JANUVIA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(1 year, 11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 MERCK SHARP DOHME Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7459428 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 years ago)

US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 years ago)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 10 months ago)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 10 months ago)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2011
M(M-244) Aug 12, 2022
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Jun 04, 2024

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 16 October, 2006

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin....

Dosage: TABLET

How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage

JANUVIA family patents

Family Patents

16. Kimyrsa patent expiration

KIMYRSA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(4 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 06, 2019
New Product(NP) Mar 12, 2024
Generating Antibiotic Incentives Now(GAIN) Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER

More Information on Dosage

KIMYRSA family patents

Family Patents

17. Mayzent patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
Aug, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(6 years from now)

US12071402 NOVARTIS Immunosuppressant formulations
Jan, 2032

(7 years from now)

US11944602 NOVARTIS Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Jul, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 26, 2024
M(M-274) Mar 01, 2025

Drugs and Companies using SIPONIMOD ingredient

NCE-1 date: 27 March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically ...

Dosage: TABLET

How can I launch a generic of MAYZENT before it's drug patent expiration?
More Information on Dosage

MAYZENT family patents

Family Patents

18. Multrys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11786548 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)

US11998565 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)

US11975022 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2024

Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient

NCE-1 date: 01 May, 2023

Market Authorisation Date: 30 June, 2021

Treatment: Neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or ...

Dosage: SOLUTION

More Information on Dosage

MULTRYS family patents

Family Patents

19. Myrbetriq patent expiration

MYRBETRIQ's oppositions filed in EPO
MYRBETRIQ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699503 APGDI Hydrogel-forming sustained-release preparation
Sep, 2013

(11 years ago)

US6346532 APGDI Amide derivatives or salts thereof
Oct, 2018

(6 years ago)

US6562375 APGDI Stable pharmaceutical composition for oral use
Aug, 2020

(4 years ago)

US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(2 years ago)

US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(1 year, 27 days ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(1 year, 27 days ago)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(1 year, 27 days ago)

USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(1 year, 27 days ago)

US7750029 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Dec, 2023

(11 months ago)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(6 months ago)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(6 months ago)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(6 months ago)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(6 months ago)

US8772315 APGDI Pharmaceutical composition for treating overactive bladder
Oct, 2028

(3 years from now)

US8772315

(Pediatric)

APGDI Pharmaceutical composition for treating overactive bladder
Apr, 2029

(4 years from now)

US12059409 APGDI Pharmaceutical composition for modified release
Sep, 2029

(4 years from now)

US12097189 APGDI Pharmaceutical composition for modified release
Sep, 2029

(4 years from now)

US10842780 APGDI Pharmaceutical composition for modified release
Sep, 2029

(4 years from now)

US11707451 APGDI Pharmaceutical composition for modified release
Sep, 2029

(4 years from now)

US10842780

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(5 years from now)

US11707451

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 28, 2017
New Indication(I-777) Apr 27, 2021
New Indication(I-855) Mar 25, 2024
Pediatric Exclusivity(PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

NCE-1 date: 26 September, 2023

Market Authorisation Date: 28 June, 2012

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Treatment of overactive bladder with symptoms of urge urinary incontinence, ur...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage

MYRBETRIQ family patents

Family Patents

20. Nourianz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(17 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders
Jan, 2023

(1 year, 10 months ago)

US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound
Sep, 2027

(2 years from now)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
Jan, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2024

Drugs and Companies using ISTRADEFYLLINE ingredient

NCE-1 date: 28 August, 2023

Market Authorisation Date: 27 August, 2019

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...

Dosage: TABLET

More Information on Dosage

NOURIANZ family patents

Family Patents

21. Nubeqa patent expiration

NUBEQA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(5 years from now)

US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(5 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(5 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Mar, 2033

(8 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 30, 2024
New Indication(I-900) Aug 05, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 31 July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET

More Information on Dosage

NUBEQA family patents

Family Patents

22. Orbactiv patent expiration

ORBACTIV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5998581 MELINTA THERAP Reductive alkylation of glycopeptide antibiotics
Nov, 2017

(7 years ago)

US5840684 MELINTA THERAP Glycopeptide antibiotic derivatives
Nov, 2020

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(4 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(5 years from now)

US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 06, 2019
Generating Antibiotic Incentives Now(GAIN) Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Dosage: POWDER

More Information on Dosage

ORBACTIV family patents

Family Patents

23. Oxbryta patent expiration

OXBRYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(8 years from now)

US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(8 years from now)

US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Nov, 2033

(8 years from now)

US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin
Dec, 2032

(8 years from now)

US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin
Jan, 2034

(9 years from now)

US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

US11944612 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(12 years from now)

US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(12 years from now)

US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-281) Nov 25, 2026
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 14 October, 2022

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering voxelotor and another active agent; Treatment of sickle cell disease b...

Dosage: TABLET

More Information on Dosage

OXBRYTA family patents

Family Patents

24. Piqray patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(4 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 24, 2024
New Indication(I-937) Jan 18, 2027

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET

More Information on Dosage

PIQRAY family patents

Family Patents

25. Pradaxa patent expiration

PRADAXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6087380 BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Dec, 2021

(2 years ago)

US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6087380 BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Feb, 2018

(6 years ago)

US6087380

(Pediatric)

BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Jun, 2022

(2 years ago)

US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Jun, 2023

(1 year, 5 months ago)

US9925174

(Pediatric)

BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Dec, 2023

(11 months ago)

US7932273

(Pediatric)

BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Mar, 2026

(1 year, 3 months from now)

US7866474 BOEHRINGER INGELHEIM Film container
Aug, 2027

(2 years from now)

US7866474

(Pediatric)

BOEHRINGER INGELHEIM Film container
Mar, 2028

(3 years from now)

US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jan, 2031

(6 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 19, 2015
New Indication(I-682) Apr 04, 2017
New Indication(I-683) Apr 04, 2017
M(M-168) Nov 20, 2018
New Strength(NS) Nov 20, 2018
New Indication(I-862) Jun 21, 2024
New Product(NP) Jun 21, 2024
Pediatric Exclusivity(PED) Dec 21, 2024

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

NCE-1 date: 22 December, 2023

Market Authorisation Date: 19 October, 2010

Treatment: Inhibition of thrombin; Method of reversing the anticoagulant effect of dabigatran using idarucizumab; Prophylaxis or treatment of venous and arterial thrombotic disease

Dosage: CAPSULE

How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage

PRADAXA family patents

Family Patents

26. Rinvoq patent expiration

RINVOQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8962629 ABBVIE Tricyclic compounds
Jan, 2031

(6 years from now)

USRE47221 ABBVIE Tricyclic compounds
Aug, 2033

(8 years from now)

US10981923 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11186584 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11773105 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11661425 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11680069 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US9951080 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11718627 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11365198 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11198697 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US10344036 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US10202393 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US10981924 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US12091415 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US12077545 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11787815 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11780847 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US9963459 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Oct, 2036

(11 years from now)

US10730883 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11780848 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US10519164 ABBVIE Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US10597400 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US10995095 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11767326 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11795175 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11512092 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11524964 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11976077 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof
Oct, 2036

(11 years from now)

US10550126 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11535624 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11535625 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11535626 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11773106 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11993605 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11993606 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US12103933 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11564922 ABBVIE Methods of treating crohn's disease and ulcerative colitis
Mar, 2038

(13 years from now)

US11607411 ABBVIE Methods of treating Crohn's disease and ulcerative colitis
Mar, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2024
New Indication(I-880) Dec 14, 2024
New Indication(I-883) Jan 14, 2025
New Indication(I-886) Mar 16, 2025
New Indication(I-888) Apr 29, 2025
New Indication(I-919) May 18, 2026
New Indication(I-946) Apr 26, 2027
New Patient Population(NPP) Apr 26, 2027
Orphan Drug Exclusivity(ODE-481) Apr 26, 2031

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had ...

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

RINVOQ family patents

Family Patents

27. Rinvoq Lq patent expiration

RINVOQ LQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8962629 ABBVIE Tricyclic compounds
Jan, 2031

(6 years from now)

USRE47221 ABBVIE Tricyclic compounds
Aug, 2033

(8 years from now)

US11680069 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US10981923 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US9951080 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11718627 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11661425 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11773105 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US11186584 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)

US12110298 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2024
New Product(NP) Apr 26, 2027
Orphan Drug Exclusivity(ODE-481) Apr 26, 2031

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 26 April, 2024

Treatment: Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: SOLUTION

More Information on Dosage

RINVOQ LQ family patents

Family Patents

28. Rozlytrek patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(3 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(4 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(8 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(3 years from now)

US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(3 years from now)

US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(3 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(3 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(8 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells
Feb, 2035

(10 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma
Feb, 2035

(10 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(12 years from now)

US11253515 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(13 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 15, 2024
Orphan Drug Exclusivity(ODE-265) Aug 15, 2026
Orphan Drug Exclusivity(ODE-313) Aug 15, 2026
New Product(NP) Oct 20, 2026
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-448) Oct 20, 2030

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 16 August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrop...

Dosage: CAPSULE

More Information on Dosage

ROZLYTREK family patents

Family Patents

29. Scenesse patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject
Feb, 2025

(2 months from now)

US8334265 CLIVUNEL INC Method of treatment of photodermatoses
Mar, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 08, 2024
Orphan Drug Exclusivity(ODE-270) Oct 08, 2026

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: 09 October, 2023

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT

More Information on Dosage

SCENESSE family patents

Family Patents

30. Selenious Acid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11998565 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2024

Drugs and Companies using SELENIOUS ACID ingredient

NCE-1 date: 01 May, 2023

Market Authorisation Date: 30 August, 2021

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SELENIOUS ACID family patents

Family Patents

31. Sivextro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(3 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(3 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 20, 2019
New Patient Population(NPP) Jun 19, 2023
Generating Antibiotic Incentives Now(GAIN) Jun 20, 2024

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: 21 June, 2023

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: POWDER; TABLET

More Information on Dosage

SIVEXTRO family patents

Family Patents

32. Sovaldi patent expiration

SOVALDI's oppositions filed in EPO
SOVALDI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(4 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(4 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(5 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(3 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(3 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(3 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(4 years from now)

US9549941 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(4 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(4 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(4 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(4 years from now)

US9549941

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(4 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(6 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 06, 2018
New Patient Population(NPP) Apr 07, 2020
Orphan Drug Exclusivity(ODE) Apr 07, 2024
ODE*(ODE*) Aug 28, 2026
Orphan Drug Exclusivity(ODE-135) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE-258) Aug 28, 2026

Drugs and Companies using SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin

Dosage: TABLET

How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage

SOVALDI family patents

Family Patents

33. Sunosi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9604917 AXSOME MALTA Treatment of sleep-wake disorders
Jun, 2026

(1 year, 6 months from now)

US8877806 AXSOME MALTA Treatment of sleep-wake disorders
Jun, 2026

(1 year, 6 months from now)

US11753368 AXSOME MALTA Treatment of sleep-wake disorders
Jun, 2026

(1 year, 6 months from now)

US10351517 AXSOME MALTA Treatment of sleep-wake disorders
Jun, 2026

(1 year, 6 months from now)

US8440715 AXSOME MALTA Treatment of sleep-wake disorders
Jun, 2031

(6 years from now)

US10512609 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)

US10195151 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)

US11998639 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)

US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(12 years from now)

US11648232 AXSOME MALTA Methods and compositions for treating excessive sleepiness
Jun, 2038

(13 years from now)

US10959976 AXSOME MALTA Methods and compositions for treating excessive sleepiness
Jun, 2038

(13 years from now)

US11865098 AXSOME MALTA Methods and compositions for treating excessive sleepiness
Jun, 2038

(13 years from now)

US10912754 AXSOME MALTA Methods and compositions for treating excessive sleepiness
Jun, 2038

(13 years from now)

US11560354 AXSOME MALTA Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
Mar, 2039

(14 years from now)

US11850226 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850227 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850228 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11857528 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11986455 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11986454 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839598 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839599 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11969404 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US10940133 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US12102609 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12064411 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12005036 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11771667 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11771666 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11872204 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11872203 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12036194 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11779554 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12090126 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11793776 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
Orphan Drug Exclusivity(ODE-254) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness with a dosing regimen ...

Dosage: TABLET

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

34. Toviaz patent expiration

TOVIAZ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7855230 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US7985772 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US7384980 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US8338478 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(2 years ago)

US6858650

(Pediatric)

PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jan, 2023

(1 year, 10 months ago)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)

US8501723 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)

US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)

US8088398

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

US7807715

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

US8501723

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2013
New Indication(I-861) Jun 17, 2024
Pediatric Exclusivity(PED) Dec 17, 2024

Drugs and Companies using FESOTERODINE FUMARATE ingredient

NCE-1 date: 18 December, 2023

Market Authorisation Date: 31 October, 2008

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of TOVIAZ before it's drug patent expiration?